Cargando…

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Marron, Servando E., Tomas-Aragones, Lucia, Moncin-Torres, Carlos A., Gomez-Barrera, Manuel, de Aranibar, Francisco Javier Garcia-Latasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305918/
https://www.ncbi.nlm.nih.gov/pubmed/34202315
http://dx.doi.org/10.3390/life11070617
_version_ 1783727686188793856
author Marron, Servando E.
Tomas-Aragones, Lucia
Moncin-Torres, Carlos A.
Gomez-Barrera, Manuel
de Aranibar, Francisco Javier Garcia-Latasa
author_facet Marron, Servando E.
Tomas-Aragones, Lucia
Moncin-Torres, Carlos A.
Gomez-Barrera, Manuel
de Aranibar, Francisco Javier Garcia-Latasa
author_sort Marron, Servando E.
collection PubMed
description Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile.
format Online
Article
Text
id pubmed-8305918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83059182021-07-25 Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results Marron, Servando E. Tomas-Aragones, Lucia Moncin-Torres, Carlos A. Gomez-Barrera, Manuel de Aranibar, Francisco Javier Garcia-Latasa Life (Basel) Article Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile. MDPI 2021-06-25 /pmc/articles/PMC8305918/ /pubmed/34202315 http://dx.doi.org/10.3390/life11070617 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marron, Servando E.
Tomas-Aragones, Lucia
Moncin-Torres, Carlos A.
Gomez-Barrera, Manuel
de Aranibar, Francisco Javier Garcia-Latasa
Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title_full Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title_fullStr Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title_full_unstemmed Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title_short Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
title_sort patient reported outcome measure in atopic dermatitis patients treated with dupilumab: 52-weeks results
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305918/
https://www.ncbi.nlm.nih.gov/pubmed/34202315
http://dx.doi.org/10.3390/life11070617
work_keys_str_mv AT marronservandoe patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults
AT tomasaragoneslucia patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults
AT moncintorrescarlosa patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults
AT gomezbarreramanuel patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults
AT dearanibarfranciscojaviergarcialatasa patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults